In the last trading session, 49.75 million Inozyme Pharma Inc (NASDAQ:INZY) shares changed hands as the company’s beta touched 1.42. With the company’s per share price at $3.95 changed hands at $2.53 or 178.17% during last session, the market valuation stood at $255.02M. INZY’s last price was a discount, traded about -57.97% off its 52-week high of $6.24. The share price had its 52-week low at $0.72, which suggests the last value was 81.77% up since then.
Analysts gave the Inozyme Pharma Inc (INZY) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.75. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended INZY as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight.
Inozyme Pharma Inc (NASDAQ:INZY) trade information
Instantly INZY was in green as seen at the end of in last trading. With action 243.48%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 42.60%, with the 5-day performance at 243.48% in the green. However, in the 30-day time frame, Inozyme Pharma Inc (NASDAQ:INZY) is 310.69% up.
The consensus price target for the stock as assigned by Wall Street analysts is 14, meaning bulls need an upside of 71.79% from its current market value. According to analyst projections, INZY’s forecast low is 14 with 16 as the target high. To hit the forecast high, the stock’s price needs a -305.06% plunge from its current level, while the stock would need to soar -254.43% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -13.98%. The 2025 estimates are for Inozyme Pharma Inc earnings to increase by 11.66%, but the outlook for the next 5-year period is at 21.72% per year.
INZY Dividends
Inozyme Pharma Inc is expected to release its next quarterly earnings report in June.
PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC holds the second largest percentage of outstanding shares, with 7.2563% or 4.49 million shares worth $20.05 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 2.22 shares estimated at $8.77 million under it, the former controlled 3.44% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.41% of the shares, roughly 1.56 shares worth around $6.15 million.
